Zilbrysq is a medication containing the active ingredient dihydroartemisinin [1]. It is formulated for oral administration as tablets [1]. Each tablet contains 100 mg of dihydroartemisinin [1].
What is Zilbrysq used for?
Zilbrysq is indicated for the treatment of malaria [1]. It is specifically used for the treatment of acute, uncomplicated Plasmodium falciparum malaria in patients weighing 20 kg or more [1].
What is dihydroartemisinin?
Dihydroartemisinin is the active metabolite of artemisinin, a compound derived from the plant Artemisia annua [2]. It belongs to a class of drugs called artemisinins, which are potent antimalarial agents [2]. Dihydroartemisinin works by interfering with the malaria parasite's ability to eliminate toxic byproducts of hemoglobin digestion [2].
How does Zilbrysq work to treat malaria?
Zilbrysq, containing dihydroartemisinin, acts on the malaria parasite by damaging its cell membranes [2]. This damage is believed to occur through the generation of free radicals, which are highly reactive molecules [2]. The parasite's detoxification system, essential for its survival, is overwhelmed, leading to parasite death [2].
When did Zilbrysq receive approval?
Zilbrysq received its initial marketing authorization in Japan on June 20, 2019 [1].
What is the typical dosage for Zilbrysq?
The recommended dosage for Zilbrysq is 100 mg of dihydroartemisinin per day for three days, administered as a single oral dose daily [1]. The total daily dose should not exceed 100 mg, and the medication is intended for patients weighing 20 kg or more [1].
Are there any other drugs that contain dihydroartemisinin?
Yes, dihydroartemisinin is also available in combination products with piperaquine, such as Duo-Cotecxa and Artequin [3]. These combination therapies are widely used for the treatment of uncomplicated malaria, particularly in regions where resistance to older antimalarials is prevalent [3].
Where can I find more information about drug patents for Zilbrysq?
Information regarding patents for Zilbrysq and other pharmaceuticals can be found on DrugPatentWatch.com [4]. This resource provides details on patent status, expiry dates, and related intellectual property for various drugs.
What are the risks associated with Zilbrysq?
The most common adverse reactions reported with Zilbrysq include headache and vomiting [1]. It is important to consult with a healthcare professional for a complete list of potential side effects and contraindications [1].
Who makes Zilbrysq?
Zilbrysq is manufactured by Kissei Pharmaceutical Co., Ltd. [1].
Sources
1. https://www.drugpatentwatch.com/drug/zilbrysq
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206590/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496077/
4. https://drugpatentwatch.com/